Abcam, ab247687, Anti-EAG1 antibody [EPR3802] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal EAG1 antibody. Carrier free. Suitable for WB and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR3802,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab247687 is the carrier-free version of
ab108537
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
EAG1 also known as Kv10.1 is a voltage-gated potassium channel with a molecular mass approximately 110 kDa. This protein plays a critical role in regulating membrane potential by allowing potassium ions to flow in response to voltage changes across the cell membrane. EAG1 is prominently expressed in the brain with presence noted in other tissues such as the heart and peripheral nervous system. Its activity influences the electrical excitability of neurons and has implications in cellular signaling.
Biological function summary
EAG1 is involved in key processes governing cellular excitability and proliferation. The channel contributes to setting the electrical properties of cells especially in neurons by controlling action potential dynamics. EAG1 does not typically form part of a complex but it can interact with other membrane proteins or signaling molecules modulating its activity. In certain contexts its aberrant expression can lead to altered cellular behaviors linking it to various cellular functional states.
Pathways
EAG1 engages in the regulation of the MAPK signaling pathway and is also significant in the PI3K/AKT pathway. These pathways are important for transmitting cellular signals that influence cell growth and survival. In the context of the MAPK pathway EAG1’s activity may interact with proteins such as B-Raf affecting downstream signaling events. Similarly in the PI3K/AKT pathway interactions can occur with proteins like AKT further integrating EAG1 within these essential frameworks.
EAG1 shows a connection to cancer and epilepsy. EAG1 overexpression has been documented in various cancers including breast and colon cancers where it may drive tumorigenic processes through its influence on cell proliferation and survival pathways. Moreover aberrant EAG1 function links to epilepsy potentially through its impact on neuronal excitability and neurotransmission. In these conditions EAG1 may interact with proteins such as p53 in cancer altering cell cycle control or with neurotransmitter receptors in epilepsy impacting neuronal networks.